Nuvalent Inc.

This program provides early access to the investigational drug zidesamtinib for people with advanced ROS1-positive lung cancer or other solid tumors who have run out of standard options. Participants must have tried at least one prior ROS1-targeted therapy and cannot join a forma…

This program offers the experimental drug neladalkib to adults with advanced ALK-positive non-small cell lung cancer or other ALK-positive solid tumors who have run out of standard treatment options and cannot join a clinical trial. The goal is to provide access to a promising th…

This study tests a new drug called zidesamtinib (NVL-520) in people with advanced lung cancer or other solid tumors that have a specific genetic change (ROS1-positive). The goal is to find the best dose and see how well it shrinks tumors. About 359 adults will take part. The drug…

This study tests a new drug called NVL-655 in people with advanced ALK-positive lung cancer and other solid tumors. The goal is to find the best dose and see how well it shrinks tumors. About 840 participants will take the pill daily, and researchers will monitor side effects and…

This early-stage study tests an experimental pill called NVL-330 in about 200 adults with advanced lung cancer that has a specific change in the HER2 gene. The main goals are to find a safe dose and see if the drug can shrink tumors or slow the cancer. Participants must have trie…

This study tests a new drug, NVL-655, against the current standard treatment alectinib for people with ALK-positive advanced non-small cell lung cancer who have not had prior treatment. The goal is to see if NVL-655 can delay cancer growth or death longer than alectinib. About 45…